Endometrial Hyperplasia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: END062 MIFTS: 51	Endometrial Hyperplasia Categories: Cancer diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Endometrial Hyperplasia

MalaCards integrated aliases for Endometrial Hyperplasia:

Name: Endometrial Hyperplasia ¹² ⁵⁶ ⁴⁵ ¹⁵

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0080365

MeSH ⁴⁵ D004714

Sources

Summaries for Endometrial Hyperplasia

Disease Ontology : ¹² An uterine benign neoplasm that is characterized by excessive proliferation of the cells of the endometrium.

MalaCards based summary : Endometrial Hyperplasia is related to adenocarcinoma and adenomyosis. An important gene associated with Endometrial Hyperplasia is PGR (Progesterone Receptor), and among its related pathways/superpathways are Gene Expression and Circadian entrainment. The drugs Medroxyprogesterone acetate and Levonorgestrel have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : ⁷⁷ Endometrial hyperplasia is a condition of excessive proliferation of the cells of the endometrium, or... more...

Sources

Related Diseases for Endometrial Hyperplasia

Diseases related to Endometrial Hyperplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	30.9	CTNNB1 KRAS MLH1 PTEN
2	adenomyosis	30.6	CYP19A1 ESR1 PGR
3	atypical polypoid adenomyoma	30.3	CTNNB1 MLH1
4	adenomyoma	30.3	CTNNB1 MLH1
5	endometriosis	29.9	CYP19A1 ESR1 ESR2 PGR PTEN
6	leiomyoma	29.9	CYP19A1 ESR1 ESR2 PGR
7	endometrial adenocarcinoma	29.8	CTNNB1 ESR1 ESR2 KRAS MLH1 PGR
8	adenoma	29.6	CTNNB1 KRAS MLH1 MSH2
9	lynch syndrome	29.2	CTNNB1 KRAS MLH1 MSH2 MSH6
10	endometrial cancer	29.1	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
11	colorectal cancer	28.1	CDK2 CTNNB1 ESR2 KRAS MLH1 MSH2
12	ovarian cancer	27.6	CTNNB1 ESR1 ESR2 KRAS MLH1 MSH2
13	breast cancer	26.8	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
14	breast duct papilloma	10.5	PGR PTEN
15	vestibular gland benign neoplasm	10.4	ESR1 PGR
16	bartholin's gland adenoma	10.4	ESR1 PGR
17	vulvar syringoma	10.4	ESR1 PGR
18	lung leiomyoma	10.4	ESR1 PGR
19	glassy cell carcinoma of the cervix	10.4	ESR1 PGR
20	vulvar benign neoplasm	10.4	ESR1 PGR
21	trigonitis	10.4	ESR1 PGR
22	vulvar leiomyoma	10.4	ESR1 PGR
23	predominantly cortical thymoma	10.4	ESR1 PGR
24	breast medullary carcinoma	10.4	ESR1 PGR
25	breast scirrhous carcinoma	10.4	ESR1 PGR
26	bartholin's gland benign neoplasm	10.4	ESR1 PGR
27	oncocytic breast carcinoma	10.4	ESR1 PGR
28	polycystic ovary syndrome	10.4
29	endometrial squamous cell carcinoma	10.4	ESR1 PGR
30	cribriform carcinoma	10.4	ESR1 PGR
31	postmenopausal atrophic vaginitis	10.4	ESR1 ESR2
32	endometrial mucinous adenocarcinoma	10.3	ESR1 PGR
33	benign metastasizing leiomyoma	10.3	CYP19A1 PGR
34	adenoid basal cell carcinoma	10.3	ESR1 PGR
35	apocrine adenocarcinoma	10.3	ESR1 PGR
36	peritoneal benign neoplasm	10.3	ESR1 PGR
37	colorectal cancer, hereditary nonpolyposis, type 7	10.3	MLH1 MSH2
38	synchronous bilateral breast carcinoma	10.3	ESR1 PGR PTEN
39	lower lip cancer	10.3	MLH1 MSH2
40	myoma	10.3	CYP19A1 ESR1 PGR
41	mammographic density	10.3	CYP19A1 ESR1 PGR
42	prostatic hypertrophy	10.3	CYP19A1 ESR1 PGR
43	reproductive organ benign neoplasm	10.3	CYP19A1 ESR1 PGR
44	deep angioma	10.3	ESR1 PGR
45	progesterone resistance	10.3	ESR1 ESR2 PGR
46	juvenile nasopharyngeal angiofibroma	10.3	CYP19A1 ESR1 PGR
47	breast fibroadenoma	10.3	CYP19A1 ESR1 PGR
48	anal fistula	10.3	MLH1 MSH2
49	gynecomastia	10.3	CYP19A1 ESR1 PGR
50	diffuse peritoneal leiomyomatosis	10.3	ESR1 PGR

Graphical network of the top 20 diseases related to Endometrial Hyperplasia:

Sources

Symptoms & Phenotypes for Endometrial Hyperplasia

GenomeRNAi Phenotypes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

²⁷ (show all 18)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased shRNA abundance (Z-score < -2)	GR00366-A-117	10.26	KRAS
2	Decreased shRNA abundance (Z-score < -2)	GR00366-A-139	10.26	CABLES1
3	Decreased shRNA abundance (Z-score < -2)	GR00366-A-14	10.26	MSH2
4	Decreased shRNA abundance (Z-score < -2)	GR00366-A-144	10.26	CDK2
5	Decreased shRNA abundance (Z-score < -2)	GR00366-A-145	10.26	CABLES1 KRAS
6	Decreased shRNA abundance (Z-score < -2)	GR00366-A-165	10.26	KRAS
7	Decreased shRNA abundance (Z-score < -2)	GR00366-A-193	10.26	KRAS
8	Decreased shRNA abundance (Z-score < -2)	GR00366-A-212	10.26	NCOR1
9	Decreased shRNA abundance (Z-score < -2)	GR00366-A-216	10.26	KRAS
10	Decreased shRNA abundance (Z-score < -2)	GR00366-A-27	10.26	KRAS
11	Decreased shRNA abundance (Z-score < -2)	GR00366-A-33	10.26	KRAS
12	Decreased shRNA abundance (Z-score < -2)	GR00366-A-53	10.26	CABLES1 CDK2 KRAS MSH2 NCOR1
13	Decreased shRNA abundance (Z-score < -2)	GR00366-A-66	10.26	KRAS
14	Decreased shRNA abundance (Z-score < -2)	GR00366-A-71	10.26	CABLES1
15	Decreased shRNA abundance (Z-score < -2)	GR00366-A-91	10.26	NCOR1
16	Decreased viability in esophageal squamous lineage	GR00235-A	9.81	CDK2 CTNNB1 ESR1 KRAS MLH1 NCOA1
17	Increased cell death HMECs cells	GR00103-A-0	9.35	CDK2 CTNNB1 NCOA1 PGR PTEN
18	Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)	GR00104-A-0	8.92	ESR1 ESR2 MSH2 PTEN

MGI Mouse Phenotypes related to Endometrial Hyperplasia:

⁴⁷ (show all 25)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.43	CABLES1 CDK2 CTNNB1 CYP19A1 ESR1 ESR2
2	cellular	MP:0005384	10.42	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
3	homeostasis/metabolism	MP:0005376	10.42	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
4	immune system	MP:0005387	10.41	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
5	hematopoietic system	MP:0005397	10.4	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
6	integument	MP:0010771	10.37	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
7	behavior/neurological	MP:0005386	10.36	CABLES1 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
8	growth/size/body region	MP:0005378	10.32	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
9	cardiovascular system	MP:0005385	10.26	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
10	mortality/aging	MP:0010768	10.26	CDK2 CTNNB1 ESR1 ESR2 KRAS MLH1
11	digestive/alimentary	MP:0005381	10.25	CTNNB1 CYP19A1 ESR1 ESR2 KRAS MLH1
12	embryo	MP:0005380	10.24	CDK2 CTNNB1 ESR1 KRAS NCOA1 NCOA3
13	neoplasm	MP:0002006	10.21	CABLES1 CDK2 CTNNB1 ESR1 ESR2 KRAS
14	liver/biliary system	MP:0005370	10.19	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
15	muscle	MP:0005369	10.16	CDK2 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
16	nervous system	MP:0003631	10.14	CABLES1 CTNNB1 CYP19A1 ESR1 ESR2 KRAS
17	adipose tissue	MP:0005375	10.1	CYP19A1 ESR1 ESR2 NCOA3 NCOR1 PTEN
18	hearing/vestibular/ear	MP:0005377	10.04	CTNNB1 CYP19A1 ESR2 KRAS NCOA3 RBP1
19	normal	MP:0002873	10.02	CTNNB1 CYP19A1 ESR1 ESR2 KRAS NCOA1
20	limbs/digits/tail	MP:0005371	9.99	CTNNB1 ESR1 ESR2 KRAS PGR PTEN
21	reproductive system	MP:0005389	9.97	CABLES1 CDK2 CTNNB1 CYP19A1 ESR1 ESR2
22	renal/urinary system	MP:0005367	9.86	CTNNB1 CYP19A1 ESR1 ESR2 KRAS NCOA1
23	pigmentation	MP:0001186	9.72	CTNNB1 CYP19A1 KRAS PTEN RBP1
24	skeleton	MP:0005390	9.61	CTNNB1 CYP19A1 ESR1 ESR2 KRAS NCOA1
25	vision/eye	MP:0005391	9.23	CDK2 CTNNB1 CYP19A1 KRAS MLH1 NCOA3

Sources

Drugs & Therapeutics for Endometrial Hyperplasia

Drugs for Endometrial Hyperplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Medroxyprogesterone acetate

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

71-58-9

Levonorgestrel

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

17489-40-6, 797-63-7

13109

Polyestradiol phosphate

Approved

Phase 4,Phase 3,Phase 2

28014-46-2

Estradiol

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2

50-28-2

5757

Metformin

Approved

Phase 4,Phase 2,Early Phase 1

657-24-9

14219 4091

Contraceptive Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Contraceptive Agents, Male

Phase 4,Phase 2,Phase 3,Phase 1

Hormones

Phase 4,Phase 2,Phase 3

Contraceptives, Oral

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Antineoplastic Agents, Hormonal

Phase 4,Phase 2,Phase 3,Phase 1

Hormone Antagonists

Phase 4,Phase 2,Phase 3

Progestins

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Medroxyprogesterone

Phase 4,Phase 2,Phase 3,Phase 1

520-85-4

10631

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 2,Phase 3

Estrogens

Phase 4,Phase 3,Phase 2

Estradiol 3-benzoate

Phase 4,Phase 3,Phase 2

Estradiol 17 beta-cypionate

Phase 4,Phase 3,Phase 2

Hypoglycemic Agents

Phase 4,Phase 2,Early Phase 1

Estrogens, Conjugated (USP)

Phase 4,Phase 3,Phase 2

Progesterone

Approved, Vet_approved

Phase 2, Phase 3,Phase 3,Early Phase 1

57-83-0

5994

Norethindrone

Approved

Phase 3,Phase 2,Not Applicable

68-22-4

6230

Bazedoxifene

Approved, Investigational

Phase 3

198481-32-2

Testosterone undecanoate

Approved, Investigational

Phase 3

5949-44-0

Methyltestosterone

Approved

Phase 3

58-18-4

6010

Testosterone

Approved, Experimental, Investigational

Phase 3

58-22-0, 481-30-1

6013 10204

Testosterone enanthate

Approved

Phase 3

315-37-7

9416

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 2, Phase 3

595-33-5

11683

Drospirenone

Approved

Phase 3

67392-87-4

68873

Sodium Citrate

Approved, Investigational

Phase 3

68-04-2

Tamoxifen

Approved

Phase 3

10540-29-1

2733526

Toremifene

Approved, Investigational

Phase 3

89778-26-7

3005573

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Deslorelin

Investigational, Vet_approved

Phase 2, Phase 3

57773-65-6

Norethindrone Acetate

Phase 3,Phase 2,Not Applicable

Bone Density Conservation Agents

Phase 3

Selective Estrogen Receptor Modulators

Phase 3

Estrogen Receptor Modulators

Phase 3

Cola

Phase 3

Estrogen Antagonists

Phase 3,Phase 2

Estrogen Receptor Antagonists

Phase 3,Phase 2

Raloxifene Hydrochloride

Phase 3

Testosterone 17 beta-cypionate

Phase 3

Anabolic Agents

Phase 3

Androgens

Phase 3

Megestrol

Phase 2, Phase 3

3562-63-8

19090 3080587

Appetite Stimulants

Phase 2, Phase 3

Central Nervous System Stimulants

Phase 2, Phase 3

Mineralocorticoid Receptor Antagonists

Phase 3

Natriuretic Agents

Phase 3

Mineralocorticoids

Phase 3

Interventional clinical trials:

(show top 50) (show all 71)

#	Name	Status	NCT ID	Phase	Drugs
1	A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia	Unknown status	NCT01074892	Phase 4	Provera (medroxyprogesterone/progestin);Provera (medroxyprogesterone)
2	Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia	Completed	NCT02872818	Phase 4	17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
3	Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients	Completed	NCT03032848	Phase 4	Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
4	Effect of Hormone Replacement Therapy on Lupus Activity	Completed	NCT00392093	Phase 4	Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
5	MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia	Not yet recruiting	NCT03675139	Phase 2, Phase 3	Medroxyprogesterone Acetate;Dydrogesterone 10 MG
6	Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC	Recruiting	NCT03463252	Phase 2, Phase 3	Progesterone;GnRH agonist
7	Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women	Completed	NCT00242710	Phase 3	Bazedoxifene/Conjugated Estrogen;Bazedoxifene/Conjugated Estrogen;CE 0.45 mg/MPA 1.5mg
8	Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome	Terminated	NCT00566644	Phase 3
9	Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women	Completed	NCT00675688	Phase 3	Bazedoxifene/Conjugate Estrogens (CE);Raloxifene;Placebo
10	Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women	Completed	NCT00467259	Phase 3	Testosterone Transdermal System;Placebo patch
11	Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia	Recruiting	NCT03241888	Phase 2, Phase 3	Megestrol Acetate
12	Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis	Completed	NCT00808132	Phase 3	bazedoxifene 20 mg/ conjugated estrogens 0.45 mg;bazedoxifene 20 mg/ conjugated estrogens 0.625 mg;bazedoxifene 20 mg;conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg;Placebo
13	Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis	Completed	NCT00431132	Phase 3	estradiol, 10 mcg
14	Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women	Completed	NCT00490087	Phase 3
15	Endometrial Safety Study	Completed	NCT00522873	Phase 3	0.25mg DRSP / 0.5mg E2 (BAY86-4891);0.5mg NETA / 1.0mg E2 (Activella)
16	Evaluate Long-Term Safety and Efficacy WC3011	Completed	NCT01455597	Phase 3	Estradiol Vaginal Gel
17	Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination	Completed	NCT00160316	Phase 3	0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
18	A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms	Completed	NCT01942668	Phase 3	Estradiol;Progesterone;Placebo
19	Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer	Recruiting	NCT03351062	Phase 3	Tamoxifen;Toremifene
20	Heart and Estrogen-Progestin Replacement Study (HERS)	Completed	NCT00319566	Phase 3	Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
21	Management of Endometrial Hyperplasia With a LNG-IUS: Multicenter Study: KGOG2006	Unknown status	NCT01234818	Phase 2
22	Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen	Unknown status	NCT00919919	Phase 2	progesterone;activella
23	The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy	Unknown status	NCT02335203	Phase 2	Depot medroxyprogesterone acetate
24	Genistein and Endometrial Hyperplasia	Completed	NCT00453960	Phase 2	Norethisterone Acetate
25	Treatment of Endometrial Hyperplasia With an Intrauterine Device (IUD)	Withdrawn	NCT00123175	Phase 1, Phase 2
26	Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate	Completed	NCT00483327	Phase 2	Megestrol Acetate
27	Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia	Terminated	NCT00503581	Phase 2	Megestrol Acetate
28	Improving the Treatment for Women With Early Stage Cancer of the Uterus	Recruiting	NCT01686126	Phase 2	Levonorgestrel;Metformin
29	Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer	Withdrawn	NCT01943058	Phase 2	megestrol acetate
30	Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer	Recruiting	NCT03300557	Phase 2	Exemestane
31	Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer	Terminated	NCT00003179	Phase 2	medroxyprogesterone
32	Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding	Recruiting	NCT03176992	Phase 2	SURGICEL®
33	Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer	Recruiting	NCT02397083	Phase 2	Everolimus
34	Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A	Terminated	NCT02600286	Phase 2	EllaOne;EllaOne placebo
35	Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids	Completed	NCT02465814	Phase 2	Vilaprisan (BAY1002670);Vilaprisan (BAY1002670;Vilaprisan (BAY1002670;Vilaprisan (BAY1002670);Ulipristal;Ulipristal;Ulipristal
36	Soy Estrogen Alternative Study (SEA)	Completed	NCT00000612	Phase 2	estrogens, conjugated
37	A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women	Completed	NCT00152282	Phase 2	Asoprisnil/Premarin;Asoprisnil/Premarin;Asoprisnil/Premarin;Placebo and Premarin
38	Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms	Active, not recruiting	NCT03541200	Phase 2	MT-8554
39	Irisin Hormone Levels in Endometrial Hyperplasia	Unknown status	NCT02903797
40	Comparison of Dilatation & Curettage and Endometrial Aspiration Biopsy Accuracy in Patients Treated With Progestin for Endometrial Hyperplasia: A Korean Gynecologic Oncology Group Study	Unknown status	NCT02412072
41	Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial Hyperplasia	Unknown status	NCT01273636
42	Transvaginal Ultrasound in Women With Abnormal Uterine Bleeding	Unknown status	NCT01786798	Not Applicable
43	Progestin Treatment for Endometrial Stromal Cells in Adenomyosis	Unknown status	NCT00155051
44	Incidence of Malignant and Premalignant Endometrial Polyp in Asymptomatic and Symptomatic Postmenopausal Women	Unknown status	NCT01203176	Not Applicable
45	Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women	Completed	NCT01499602	Not Applicable	LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland;Norethisterone Acetate tablets
46	Women With Asymptomatic Endometrial Hyperplasia	Completed	NCT02100137
47	Ultrasound and Endometrial Hyperplasia	Terminated	NCT00123188	Not Applicable
48	Metformin for the Treatment of Endometrial Hyperplasia	Completed	NCT01685762	Early Phase 1	Metformin
49	Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer	Active, not recruiting	NCT00339651
50	Role of Senescence in the Development of Endometrial Cancer	Recruiting	NCT03338985	Not Applicable

Search NIH Clinical Center for Endometrial Hyperplasia

Cochrane evidence based reviews: endometrial hyperplasia

Sources

Genetic Tests for Endometrial Hyperplasia

Sources

Anatomical Context for Endometrial Hyperplasia

MalaCards organs/tissues related to Endometrial Hyperplasia:

⁴²

Uterus, Ovary, Testes, Breast, Bone, Heart, Endothelial

Sources

Publications for Endometrial Hyperplasia

Articles related to Endometrial Hyperplasia:

(show top 50) (show all 766)

#	Title	Authors	Year
1	Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. ( 30793281 )	Travaglino A...Zullo F	2019
2	Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia. ( 30826750 )	Wang Y...Wang J	2019
3	Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer, In Vivo and the Impact of Metformin In Vitro. ( 30745857 )	Wang T...Billig H	2019
4	Melatonin reduced endometrial hyperplasia induced by estradiol in female albino rats. ( 30657459 )	Abdel-Hamid HA...Toni ND	2019
5	Could E-Cadherin and CD10 Expression be Used to Differentiate Between Atypical Endometrial Hyperplasia and Endometrial Carcinoma? ( 30726192 )	Youssef MY...Mohamed MA	2019
6	Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. ( 30779338 )	Raffone A...Zullo F	2019
7	Ovarian insufficiency and CTNNB1 mutations drive malignant transformation of endometrial hyperplasia with altered PTEN/PI3K activities. ( 30782821 )	Terakawa J...Kurita T	2019
8	Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. ( 30802329 )	Travaglino A...Zullo F	2019
9	PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? ( 30803040 )	Travaglino A...Zullo F	2019
10	Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. ( 30810881 )	Raffone A...Zullo F	2019
11	Predicting risk of relapse in endometrial hyperplasia. ( 30822371 )	De Silva PM...Gallos ID	2019
12	Atypical Endometrial Hyperplasia Diagnosed by Hysteroscopic Photodynamic Diagnosis using 5-Aminolevulinic Acid. ( 30849521 )	Matoba Y...Aoki D	2019
13	Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience. ( 30887764 )	Wang Y...Ma C	2019
14	Characteristics of patients with endometrial hyperplasia under different air quality index conditions. ( 30910154 )	Chang FW...Liu SH	2019
15	PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. ( 30915635 )	Raffone A...Zullo F	2019
16	Role of Morphometry and Matrix Metalloproteinase-9 Expression in Differentiating between Atypical Endometrial Hyperplasia and Low Grade Endometrial Adenocarcinoma ( 30139240 )	Assaf MI...Mohamed EA	2018
17	PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. ( 30342311 )	Travaglino A...Zullo F	2018
18	Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥11 mm: A systematic review and meta-analysis. ( 30113073 )	Alc?zar JL...Salas A	2018
19	Maternal obesogenic diet induces endometrial hyperplasia, an early hallmark of endometrial cancer, in a diethylstilbestrol mouse model. ( 29775456 )	Owuor TO...Moley KH	2018
20	Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study. ( 30017893 )	Giampaolino P...Bifulco G	2018
21	Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? ( 29400014 )	Yamagami W...Aoki D	2018
22	Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer. ( 29121428 )	Tamauchi S...Kikkawa F	2018
23	The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia. ( 28715800 )	Uysal G...Karakilic EU	2018
24	Endometrial Polyps and Benign Endometrial Hyperplasia Have Increased Prevalence of DNA Fragmentation Factors 40 and 45 (DFF40 and DFF45) Together With the Antiapoptotic B-Cell Lymphoma (Bcl-2) Protein Compared With Normal Human Endometria. ( 28914671 )	Banas T...Cielecka-Kuszyk J	2018
25	Mutation analysis by whole exome sequencing of endometrial hyperplasia and carcinoma in one patient: Abnormalities of polymerase epsilon and the phosphatidylinositol-3 kinase pathway. ( 28984400 )	Miyamoto T...Shiozawa T	2018
26	Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women. ( 29133593 )	Sahoo SS...Tanwar PS	2018
27	Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: involvement of the bcl-2 family proteins. ( 29179590 )	Sahin E...Saatci C	2018
28	Expression of p53, Bcl-2 and Bax in endometrial carcinoma, endometrial hyperplasia and normal endometrium: a histopathological study. ( 29560769 )	Mirakhor Samani S...Fouladi DF	2018
29	Proliferative and apoptotic changes in the healthy canine endometrium and in cystic endometrial hyperplasia. ( 29574305 )	Reusche N...G?nzel-Apel AR	2018
30	Can concurrent high-risk endometrial carcinoma occur with atypical endometrial hyperplasia? ( 29665453 )	Erdem B...Akbay?r ?	2018
31	RNA sequencing reveals significant miRNAs in Atypical endometrial hyperplasia. ( 29709726 )	Tang S...Dai Y	2018
32	Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study. ( 29715112 )	Sletten ET...?rbo A	2018
33	Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia. ( 30013435 )	Matsuzaki T...Irahara M	2018
34	Surgical management of complex atypical endometrial hyperplasia in a woman with rare genitourinary anomalies: unicornuate uterus with rudimentary horn, ipsilateral ectopic ovary and pelvic kidney. ( 30039793 )	Grigoriadis C...Hassiakos D	2018
35	Mechanisms underlying the protective effect of montelukast in prevention of endometrial hyperplasia in female rats. ( 30056375 )	Abdelzaher WY...Sanad AS	2018
36	Hypoxia is involved in the reduction of HtrA3 in patients with endometrial hyperplasia and cancer. ( 30139517 )	Lv Q...Chen Q	2018
37	Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: A specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis. ( 30168854 )	Travaglino A...Zullo F	2018
38	Contrast enhanced ultrasound in diagnosis of endometrial carcinoma and endometrial hyperplasia. ( 30213295 )	Su Q...Lv G	2018
39	Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients. ( 30255125 )	Graul A...Kim SH	2018
40	DNA Repair Gene (XPD, XRCC4, and XRCC1) Polymorphisms in Patients with Endometrial Hyperplasia: A Pilot Study. ( 30275440 )	?zt?rk E...Erk?l?? S	2018
41	Endometrial hyperplasia and risk of coexistent cancer: WHO vs EIN criteria. ( 30347477 )	Travaglino A...Zullo F	2018
42	The Effects of Folic Acid Supplementation on Recurrence and Metabolic Status in Endometrial Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled Trial. ( 30415553 )	Bahmani F...Asemi Z	2018
43	PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy. ( 30511741 )	Raffone A...Zullo F	2018
44	Oral and intrauterine progestogens for atypical endometrial hyperplasia. ( 30521671 )	Luo L...Sidell N	2018
45	Does surgical treatment of atypical endometrial hyperplasia require referral to a gynecologic oncologist? ( 30527944 )	Shalowitz DI...Schoenbachler N	2018
46	Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study. ( 30548528 )	Sletten ET...?rbo A	2018
47	Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice. ( 27980219 )	Bajwa P....Tanwar P.S.	2017
48	A Case Report: Ovarian Sertoli-Leydig Cell Tumor With Hyperestrogenism and Endometrial Hyperplasia in a Postmenopausal Woman. ( 28469526 )	Tsuzuki Y....Tomita S.	2017
49	Angioedema attacks related to endometrial hyperplasia in a case of estrogen-dependent factor XII hereditary angioedema. ( 28476524 )	Prieto-Garc?a A...Baeza ML	2017
50	Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management. ( 28698465 )	Nwanodi O	2017

Sources

Genes for Endometrial Hyperplasia

Genes related to Endometrial Hyperplasia (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	PGR	Progesterone Receptor	Protein Coding	33.88	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	7922983 20199355 16831363 (more) 15863148 14735466 11873308 18839858 18528284 9159337 14747944 18287870 11251965 11443221 14501812 9221798 12684894 10756900 16575402
2	PTEN	Phosphatase And Tensin Homolog	Protein Coding	33.36	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18788685 19224164 9635567 (more) 12459636 16764775 12405911 15948123 11873308 11818530 15385114 10955808 12649668 18632658 16909866 17085648 17466036 15583796 20079187 19696618 17009632
3	ESR1	Estrogen Receptor 1	Protein Coding	33.05	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	7922983 16325240 16831363 (more) 17561234 11251965 1876529 10756900 15882182 18250990 14559803 11336777 8491764 15800680 9221798 19759112 11820567 16575402 14601091 12684894 9345349 16633364 14501812 20107426 18720455 16677694 18528284 15644579
4	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	28.76	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	8371007 16831363 17889878 (more) 20199355 19301987 16493257
5	ESR2	Estrogen Receptor 2	Protein Coding	27.54	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15882182 16325240 11820567
6	MLH1	MutL Homolog 1	Protein Coding	27.52	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	11291077 12801268 10550333 (more) 14614055 11054716 17089036 12649668 16099019
7	MSH2	MutS Homolog 2	Protein Coding	26.99	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	11291077 12801268 11054716 (more) 15350299 12649668
8	CTNNB1	Catenin Beta 1	Protein Coding	26.95	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	10411147 20079187
9	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	26.77	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	19419940
10	MSH6	MutS Homolog 6	Protein Coding	26.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	12649668
11	RBP1	Retinol Binding Protein 1	Protein Coding	26.43	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	16575402 15500655
12	NCOR1	Nuclear Receptor Corepressor 1	Protein Coding	25.79	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	14601091
13	CDK2	Cyclin Dependent Kinase 2	Protein Coding	25.39	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	17483252 19631369 12684894
14	CABLES1	Cdk5 And Abl Enzyme Substrate 1	Protein Coding	25.37	GeneCards inferred via : Publications Expressions (show sections)
15	NCOA3	Nuclear Receptor Coactivator 3	Protein Coding	24.75	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	16980945
16	NCOA1	Nuclear Receptor Coactivator 1	Protein Coding	24.19	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	14601091

Sources

Variations for Endometrial Hyperplasia

Sources

Expression for Endometrial Hyperplasia

Search GEO for disease gene expression data for Endometrial Hyperplasia.

Sources

Pathways for Endometrial Hyperplasia

Pathways related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 38)

#	Super pathways	Score	Top Affiliating Genes
1	Gene Expression ⁶⁷ Show member pathways Generic Transcription Pathway ⁶⁷	13.72	CDK2 ESR1 ESR2 MLH1 MSH2 NCOA1
2	Circadian entrainment ³⁸ Show member pathways Cholinergic synapse ³⁸ Dopaminergic synapse ³⁸ Estrogen signaling pathway ³⁸ Glutamatergic synapse ³⁸ Relaxin receptors ⁶⁷ Relaxin signaling pathway ³⁸ Synaptic Neurotransmission Pathways: Glutamatergic Excitation ⁶⁶	12.96	ESR1 ESR2 KRAS NCOA1 NCOA3 PGR
3	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.78	CDK2 CTNNB1 KRAS MLH1 MSH2 MSH6
4	Chks in Checkpoint Regulation ⁶⁵ Show member pathways DNA Repair Mechanisms ⁶⁵ Estrogen-mediated S-Phase Entry ⁶⁵ G2-M Phase Transition ⁶⁵ Parkinson's Disease Pathway ⁶⁵ SREBP Proteolysis ⁶⁵	12.63	CDK2 ESR1 ESR2 MSH2 MSH6
5	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.57	CDK2 ESR1 ESR2 KRAS MSH6 NCOA3
6	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.52	CDK2 CTNNB1 ESR1 ESR2 KRAS MLH1
7	Prolactin Signaling Pathway ¹ ³⁸ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.44	ESR1 ESR2 KRAS NCOA1 PTEN
8	DNA Damage ⁴	12.43	CDK2 MLH1 MSH2 MSH6
9	Pathways in cancer ³⁸	12.42	CDK2 CTNNB1 ESR1 ESR2 KRAS MLH1
10	Development Ligand-independent activation of ESR1 and ESR2 ²³ Show member pathways Transcription CREB pathway ²³ Transcription PPAR Pathway ²³	12.26	ESR1 ESR2 NCOA1 NCOA3 NCOR1
11	Colorectal Cancer Metastasis ⁶⁵	12.13	CTNNB1 KRAS MLH1 MSH2 MSH6
12	Cell cycle Role of SCF complex in cell cycle regulation ²³ Show member pathways Cell cycle ESR1 regulation of G1/S transition ²³ Cell cycle Regulation of G1/S transition (part 1) ²³ Immune response MIF-JAB1 signaling ²³	12.13	CDK2 ESR1 NCOA1 NCOA3 NCOR1 PGR
13	Transcription Androgen Receptor nuclear signaling ²³ Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²³	12.07	CTNNB1 NCOA1 NCOR1 PTEN
14	FoxO signaling pathway ³⁸ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	11.99	CDK2 KRAS PTEN
15	Adipogenesis ¹	11.97	CTNNB1 NCOA1 NCOR1
16	Direct p53 effectors ¹	11.97	MLH1 MSH2 PTEN
17	Glioblastoma Multiforme ⁶⁵	11.93	CDK2 CTNNB1 KRAS PTEN
18	Signaling by ERBB4 ⁶⁷ Show member pathways Downregulation of ERBB4 signaling ⁶⁷ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁷	11.91	ESR1 KRAS NCOR1 PGR
19	DNA Damage Response (only ATM dependent) ¹	11.9	CTNNB1 KRAS PTEN
20	Thyroid hormone signaling pathway ³⁸	11.86	CTNNB1 ESR1 KRAS NCOA1 NCOA3 NCOR1
21	Mismatch repair ¹ ³⁸ ⁶⁷ Show member pathways Mismatch repair (MMR) directed by MSH2-MSH3 (MutSbeta) ⁶⁷ Mismatch repair (MMR) directed by MSH2-MSH6 (MutSalpha) ⁶⁷ Mismatch Repair in Eukaryotes ⁶⁵	11.83	MLH1 MSH2 MSH6
22	TGF-beta Signaling Pathways ⁶⁶	11.81	ESR1 ESR2 KRAS
23	Androgen receptor signaling pathway ¹	11.81	CTNNB1 NCOA1 NCOA3 NCOR1 PTEN
24	Nuclear Receptor transcription pathway ⁶⁷ Show member pathways Nuclear Receptors ¹	11.78	ESR1 ESR2 PGR
25	Retinoblastoma (RB) in Cancer ¹	11.77	CDK2 MSH6 RBP1
26	Regulation of nuclear SMAD2/3 signaling ¹	11.71	CDK2 ESR1 NCOA1 NCOR1
27	Platinum drug resistance ³⁸	11.68	MLH1 MSH2 MSH6
28	Transcription Ligand-dependent activation of the ESR1/SP pathway ²³ Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²³	11.66	ESR1 NCOA1 NCOA3
29	DNA damage_Role of Brca1 and Brca2 in DNA repair ²³	11.53	KRAS MLH1 MSH2 MSH6
30	Aryl Hydrocarbon Receptor ¹	11.47	CDK2 ESR1 KRAS
31	Integrated Breast Cancer Pathway ¹	11.46	CDK2 CTNNB1 CYP19A1 ESR1 KRAS MSH2
32	Integrated Cancer Pathway ¹	11.44	CDK2 MSH2 MSH6 PTEN
33	Platinum Pathway, Pharmacokinetics/Pharmacodynamics ⁶²	11.24	MLH1 MSH2 MSH6
34	Ovarian Infertility Genes ¹	11.16	CYP19A1 ESR2 MLH1 NCOR1 PGR
35	AHR Pathway ⁶⁵	11.14	ESR1 NCOA1 NCOA3
36	Retinoic acid receptors-mediated signaling ¹	11.13	NCOA1 NCOA3 RBP1
37	MNAR-PELP1 and Estrogen Receptor Interaction ⁶⁵	11.09	ESR1 ESR2 KRAS
38	Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics ⁶²	10.21	CYP19A1 ESR1 ESR2

Sources

GO Terms for Endometrial Hyperplasia

Cellular components related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nuclear chromatin	GO:0000790	9.55	ESR1 MSH6 NCOA1 NCOA3 NCOR1
2	nucleoplasm	GO:0005654	9.44	CDK2 CTNNB1 ESR1 ESR2 MLH1 MSH2
3	MutSalpha complex	GO:0032301	9.26	MSH2 MSH6
4	mismatch repair complex	GO:0032300	9.13	MLH1 MSH2 MSH6
5	nucleus	GO:0005634	10.18	CABLES1 CDK2 CTNNB1 ESR1 ESR2 MLH1
6	cytosol	GO:0005829	10.1	CABLES1 CDK2 CTNNB1 ESR1 KRAS MSH6

Biological processes related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 30)

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA repair	GO:0006281	9.94	CDK2 MLH1 MSH2 MSH6
2	positive regulation of transcription, DNA-templated	GO:0045893	9.88	CDK2 CTNNB1 ESR1 ESR2 NCOA1 NCOA3
3	response to estradiol	GO:0032355	9.79	CTNNB1 ESR1 PTEN
4	intracellular estrogen receptor signaling pathway	GO:0030520	9.65	ESR1 ESR2
5	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.65	MLH1 MSH2 MSH6
6	uterus development	GO:0060065	9.64	CYP19A1 ESR1
7	androgen metabolic process	GO:0008209	9.63	CYP19A1 ESR1
8	epithelial tube branching involved in lung morphogenesis	GO:0060441	9.63	CTNNB1 KRAS
9	androgen receptor signaling pathway	GO:0030521	9.63	CTNNB1 NCOA1 NCOA3
10	negative regulation of DNA recombination	GO:0045910	9.62	MSH2 MSH6
11	determination of adult lifespan	GO:0008340	9.62	MSH2 MSH6
12	regulation of synaptic transmission, GABAergic	GO:0032228	9.61	KRAS PTEN
13	protein localization to chromatin	GO:0071168	9.6	ESR1 MSH2
14	positive regulation of isotype switching to IgG isotypes	GO:0048304	9.59	MLH1 MSH2
15	negative regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903799	9.58	ESR1 NCOR1
16	positive regulation of helicase activity	GO:0051096	9.58	MSH2 MSH6
17	prostate gland growth	GO:0060736	9.57	CYP19A1 PTEN
18	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.56	CTNNB1 ESR1 ESR2 PTEN
19	transcription, DNA-templated	GO:0006351	9.55	ESR1 NCOA1
20	mismatch repair	GO:0006298	9.54	MLH1 MSH2 MSH6
21	maintenance of DNA repeat elements	GO:0043570	9.52	MSH2 MSH6
22	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.51	MLH1 MSH2
23	regulation of RNA biosynthetic process	GO:2001141	9.49	NCOA1 NCOA3
24	somatic hypermutation of immunoglobulin genes	GO:0016446	9.33	MLH1 MSH2 MSH6
25	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.32	MLH1 MSH2
26	pyrimidine dimer repair	GO:0006290	9.26	MSH6
27	replication fork arrest	GO:0043111	9.24	MSH6
28	meiotic mismatch repair	GO:0000710	9.13	MSH6
29	isotype switching	GO:0045190	9.13	MLH1 MSH2 MSH6
30	somatic recombination of immunoglobulin gene segments	GO:0016447	8.8	MLH1 MSH2 MSH6

Molecular functions related to Endometrial Hyperplasia according to GeneCards Suite gene sharing:

(show all 21)

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription coactivator activity	GO:0003713	9.88	CTNNB1 ESR2 NCOA1 NCOA3
2	lipid binding	GO:0008289	9.83	ESR1 ESR2 PGR PTEN RBP1
3	steroid hormone receptor activity	GO:0003707	9.71	ESR1 ESR2 PGR
4	nuclear receptor activity	GO:0004879	9.7	ESR1 ESR2 PGR
5	chromatin binding	GO:0003682	9.7	CTNNB1 ESR1 MLH1 MSH2 MSH6 NCOA1
6	androgen receptor binding	GO:0050681	9.67	CTNNB1 NCOA1 NCOA3
7	estrogen receptor binding	GO:0030331	9.65	CTNNB1 ESR1 NCOA1
8	four-way junction DNA binding	GO:0000400	9.59	MSH2 MSH6
9	MutLalpha complex binding	GO:0032405	9.58	MSH2 MSH6
10	steroid binding	GO:0005496	9.58	ESR1 ESR2 PGR
11	oxidized purine DNA binding	GO:0032357	9.57	MSH2 MSH6
12	estrogen receptor activity	GO:0030284	9.56	ESR1 ESR2
13	single thymine insertion binding	GO:0032143	9.55	MSH2 MSH6
14	estrogen response element binding	GO:0034056	9.51	ESR1 ESR2
15	mismatched DNA binding	GO:0030983	9.5	MLH1 MSH2 MSH6
16	single guanine insertion binding	GO:0032142	9.46	MSH2 MSH6
17	guanine/thymine mispair binding	GO:0032137	9.43	MLH1 MSH2 MSH6
18	nuclear receptor binding	GO:0016922	9.37	NCOA1 NCOA3
19	enzyme binding	GO:0019899	9.28	CTNNB1 ESR1 ESR2 MLH1 MSH2 MSH6
20	nuclear hormone receptor binding	GO:0035257	9.26	CTNNB1 NCOA1 NCOA3 NCOR1
21	protein binding	GO:0005515	10.44	CABLES1 CDK2 CTNNB1 ESR1 ESR2 KRAS

Sources

Sources for Endometrial Hyperplasia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia